Sanofi targets eczema-treatment product Dupixent peak sales of over 13 billion euros
Paris: French healthcare group Sanofi, which lagged rivals in the race for COVID-19 vaccines, raised on Tuesday its peak sales target for eczema-treatment product Dupixent to more than 13 billion euros ($14.3 billion).
"This new ambition does not include potential for additional sales ambition upgrade from chronic obstructive pulmonary disease (COPD), with pivotal readouts anticipated in 2023," Sanofi said in a statement.
This month, analysts at investment bank JP Morgan had said they expected Sanofi to raise its peak sales guidance for Dupixent to about $15 billion.
Read also: Sanofi joins hands with Prellis Biologics
Sanofi is working with British partner GlaxoSmithKline to develop a COVID-19 vaccine.
Sanofi also announced on Tuesday a partnership with U.S company IGM Biosciences in the field of treatments for oncology, immunology and inflammation.
Read also: Sanofi gets Japenese nod for Xenpozyme to treat acid sphingomyelinase deficiency
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.